Cargando…

Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study

OBJECTIVES: To investigate the association of alkaline phosphatase (ALP) levels with the risk of the composite end point of cardiovascular disease (CVD), and all-cause mortality as well as each of them separately. DESIGN: Prospective cohort study. SETTING: Within the framework of the Tehran Lipid an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabootari, Maryam, Raee, Mohammad Reza, Akbarpour, Samaneh, Asgari, Samaneh, Azizi, Fereidoun, Hadaegh, Farzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254490/
https://www.ncbi.nlm.nih.gov/pubmed/30478120
http://dx.doi.org/10.1136/bmjopen-2018-023735
_version_ 1783373726139547648
author Kabootari, Maryam
Raee, Mohammad Reza
Akbarpour, Samaneh
Asgari, Samaneh
Azizi, Fereidoun
Hadaegh, Farzad
author_facet Kabootari, Maryam
Raee, Mohammad Reza
Akbarpour, Samaneh
Asgari, Samaneh
Azizi, Fereidoun
Hadaegh, Farzad
author_sort Kabootari, Maryam
collection PubMed
description OBJECTIVES: To investigate the association of alkaline phosphatase (ALP) levels with the risk of the composite end point of cardiovascular disease (CVD), and all-cause mortality as well as each of them separately. DESIGN: Prospective cohort study. SETTING: Within the framework of the Tehran Lipid and Glucose Study (TLGS) cohort, participants were followed from baseline examination (1999–2001) until March 2014. PARTICIPANTS: A total of 2578 participants, aged ≥30 years free of prevalent CVD at baseline examination. PRIMARY OUTCOME: The main outcome measures were composite end point of coronary heart disease (CHD), stroke, all-cause mortality and each per se. RESULTS: During a median follow-up of 11.3 years, 369, 68, 420, 170 and 495 participants experienced CHD, stroke, CVD, all-cause mortality and the composite outcome, respectively. In the multivariable Cox regression models, the adjusted HRs (95% CI) for mentioned events per one SD increase in ALP level after full adjustment were 1.11 (1.01 to 1.22), 1.20 (0.97 to 1.49, p=0.058), 1.10 (1.01 to 1.21), 1.16 (1.01 to 1.33) and 1.11 (1.02 to 1.21), respectively. Furthermore, participants with ALP levels in the highest tertile had significant adjusted HRs (95% CI) for stroke (1.88 (1.00 to 3.61)), CVD (1.30 (1.01 to 1.68)) and composite outcome (1.27 (1.00 to 1.61)). The cut-off value of ALP ≥199 IU/L for predicting composite outcome was derived using Youden’s index, based on which this cut-off point was associated with significant risk of 80%, 26%, 43% and 26% for incident stroke, CVD, all-cause mortality and composite outcome. Additionally, no improvement was seen in the predictive ability of traditional risk factors models after adding ALP values, considering the levels of Akaike information criterion, C-index and Net Reclassification Index. CONCLUSION: Independent associations between ALP levels and the risks of CVD and mortality events were shown, despite the fact that adding the data of ALP to known risk factors did not improve the prediction of these events.
format Online
Article
Text
id pubmed-6254490
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-62544902018-12-11 Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study Kabootari, Maryam Raee, Mohammad Reza Akbarpour, Samaneh Asgari, Samaneh Azizi, Fereidoun Hadaegh, Farzad BMJ Open Cardiovascular Medicine OBJECTIVES: To investigate the association of alkaline phosphatase (ALP) levels with the risk of the composite end point of cardiovascular disease (CVD), and all-cause mortality as well as each of them separately. DESIGN: Prospective cohort study. SETTING: Within the framework of the Tehran Lipid and Glucose Study (TLGS) cohort, participants were followed from baseline examination (1999–2001) until March 2014. PARTICIPANTS: A total of 2578 participants, aged ≥30 years free of prevalent CVD at baseline examination. PRIMARY OUTCOME: The main outcome measures were composite end point of coronary heart disease (CHD), stroke, all-cause mortality and each per se. RESULTS: During a median follow-up of 11.3 years, 369, 68, 420, 170 and 495 participants experienced CHD, stroke, CVD, all-cause mortality and the composite outcome, respectively. In the multivariable Cox regression models, the adjusted HRs (95% CI) for mentioned events per one SD increase in ALP level after full adjustment were 1.11 (1.01 to 1.22), 1.20 (0.97 to 1.49, p=0.058), 1.10 (1.01 to 1.21), 1.16 (1.01 to 1.33) and 1.11 (1.02 to 1.21), respectively. Furthermore, participants with ALP levels in the highest tertile had significant adjusted HRs (95% CI) for stroke (1.88 (1.00 to 3.61)), CVD (1.30 (1.01 to 1.68)) and composite outcome (1.27 (1.00 to 1.61)). The cut-off value of ALP ≥199 IU/L for predicting composite outcome was derived using Youden’s index, based on which this cut-off point was associated with significant risk of 80%, 26%, 43% and 26% for incident stroke, CVD, all-cause mortality and composite outcome. Additionally, no improvement was seen in the predictive ability of traditional risk factors models after adding ALP values, considering the levels of Akaike information criterion, C-index and Net Reclassification Index. CONCLUSION: Independent associations between ALP levels and the risks of CVD and mortality events were shown, despite the fact that adding the data of ALP to known risk factors did not improve the prediction of these events. BMJ Publishing Group 2018-11-25 /pmc/articles/PMC6254490/ /pubmed/30478120 http://dx.doi.org/10.1136/bmjopen-2018-023735 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cardiovascular Medicine
Kabootari, Maryam
Raee, Mohammad Reza
Akbarpour, Samaneh
Asgari, Samaneh
Azizi, Fereidoun
Hadaegh, Farzad
Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study
title Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study
title_full Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study
title_fullStr Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study
title_full_unstemmed Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study
title_short Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study
title_sort serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: tehran lipid and glucose study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254490/
https://www.ncbi.nlm.nih.gov/pubmed/30478120
http://dx.doi.org/10.1136/bmjopen-2018-023735
work_keys_str_mv AT kabootarimaryam serumalkalinephosphataseandtheriskofcoronaryheartdiseasestrokeandallcausemortalitytehranlipidandglucosestudy
AT raeemohammadreza serumalkalinephosphataseandtheriskofcoronaryheartdiseasestrokeandallcausemortalitytehranlipidandglucosestudy
AT akbarpoursamaneh serumalkalinephosphataseandtheriskofcoronaryheartdiseasestrokeandallcausemortalitytehranlipidandglucosestudy
AT asgarisamaneh serumalkalinephosphataseandtheriskofcoronaryheartdiseasestrokeandallcausemortalitytehranlipidandglucosestudy
AT azizifereidoun serumalkalinephosphataseandtheriskofcoronaryheartdiseasestrokeandallcausemortalitytehranlipidandglucosestudy
AT hadaeghfarzad serumalkalinephosphataseandtheriskofcoronaryheartdiseasestrokeandallcausemortalitytehranlipidandglucosestudy